These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 19578688)

  • 1. The psychiatric side-effects of rimonabant.
    Moreira FA; Crippa JA
    Braz J Psychiatry; 2009 Jun; 31(2):145-53. PubMed ID: 19578688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation.
    Cahill K; Ussher M
    Cochrane Database Syst Rev; 2007 Oct; (4):CD005353. PubMed ID: 17943852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabinoid type 1 receptor antagonists for smoking cessation.
    Cahill K; Ussher MH
    Cochrane Database Syst Rev; 2011 Mar; 2011(3):CD005353. PubMed ID: 21412887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation.
    Cahill K; Ussher M
    Cochrane Database Syst Rev; 2007 Jul; (3):CD005353. PubMed ID: 17636794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression.
    Moreira FA; Grieb M; Lutz B
    Best Pract Res Clin Endocrinol Metab; 2009 Feb; 23(1):133-44. PubMed ID: 19285266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity.
    Christopoulou FD; Kiortsis DN
    J Clin Pharm Ther; 2011 Feb; 36(1):10-8. PubMed ID: 21198716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors.
    Gelfand EV; Cannon CP
    Expert Opin Investig Drugs; 2006 Mar; 15(3):307-15. PubMed ID: 16503766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies.
    Le Foll B; Forget B; Aubin HJ; Goldberg SR
    Addict Biol; 2008 Jun; 13(2):239-52. PubMed ID: 18482433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety of obesity drugs.
    Van Gaal LF; Scheen AJ; Formiguera X
    Expert Opin Drug Saf; 2007 Sep; 6(5):475-6; author reply 477-8. PubMed ID: 17877434
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapeutic potential of targeting the endocannabinoids: implications for the treatment of obesity, metabolic syndrome, drug abuse and smoking cessation.
    Tucci SA; Halford JC; Harrold JA; Kirkham TC
    Curr Med Chem; 2006; 13(22):2669-80. PubMed ID: 17017918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns?
    Pacher P
    Arterioscler Thromb Vasc Biol; 2009 Jan; 29(1):7-9. PubMed ID: 19092136
    [No Abstract]   [Full Text] [Related]  

  • 13. Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.
    Ward SJ; Raffa RB
    Obesity (Silver Spring); 2011 Jul; 19(7):1325-34. PubMed ID: 21475141
    [No Abstract]   [Full Text] [Related]  

  • 14. Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity.
    Leite CE; Mocelin CA; Petersen GO; Leal MB; Thiesen FV
    Pharmacol Rep; 2009; 61(2):217-24. PubMed ID: 19443932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trial comes too late as psychiatric side effects end hope for rimonabant.
    Stapleton JA
    Addiction; 2009 Feb; 104(2):277-8. PubMed ID: 19149824
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders.
    Scheen AJ; Paquot N
    Best Pract Res Clin Endocrinol Metab; 2009 Feb; 23(1):103-16. PubMed ID: 19285264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rimonabant: new drug. Obesity: loss of a few kilos, many questions.
    Prescrire Int; 2006 Aug; 15(84):123-6. PubMed ID: 16977739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
    Scheen AJ
    J Neuroendocrinol; 2008 May; 20 Suppl 1():139-46. PubMed ID: 18426513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New drugs; rimonabant].
    van Bronswijk H; Dubois EA; Pijl H; Cohen AF
    Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2620-2. PubMed ID: 18161263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabinoid receptor CB1 antagonists state of the art and challenges.
    Bifulco M; Santoro A; Laezza C; Malfitano AM
    Vitam Horm; 2009; 81():159-89. PubMed ID: 19647112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.